Forest Levothroid Misses NDA Approval Deadline; FDA Requests Withdrawal
Executive Summary
Forest Labs must cease distribution of its levothyroxine product Levothroid after failing to receive approval of its pending NDA, FDA said in a warning letter posted on the agency's website Aug. 19